{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T06:18:50Z","timestamp":1766902730842,"version":"3.41.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.prp.2025.156025","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T14:56:59Z","timestamp":1747234619000},"page":"156025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A review of the progress and challenges of developing dendritic-based vaccines against hepatitis B virus (HBV)"],"prefix":"10.1016","volume":"271","author":[{"given":"Ali","family":"Ameri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Gandomkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan Hassan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhwan Abdul","family":"Kareem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayder Naji","family":"Sameer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab H.","family":"Athab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohaned","family":"Adil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Ghasemzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/v17010060","article-title":"Hepatitis B virus in polish blood donors in the period 2005\u20132019\u2014significant changes in epidemiology and demographic characteristics of infected donors","volume":"17","author":"Kopacz","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.prp.2025.156025_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155391","article-title":"DNA damages in hepatocytes are amended by an inflammation-driven rescue repair mechanism in chronic hepatitis B","volume":"260","author":"Dong","year":"2024","journal-title":"Pathol. -Res. Pract."},{"key":"10.1016\/j.prp.2025.156025_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155232","article-title":"Prognostic value of genome-wide methylation in acute-on-chronic hepatitis B liver failure","volume":"256","author":"Li","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"01","key":"10.1016\/j.prp.2025.156025_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/ID9.0000000000000130","article-title":"Epidemiology, natural history, and outcome of chronic hepatitis B in children","volume":"5","author":"Huang","year":"2025","journal-title":"Infect. Dis. Immun."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.14041","article-title":"Predictive factors for HBsAg loss in chronic hbeag-negative hepatitis B virus infection: insights from a 5-year french cohort","volume":"32","author":"Causse","year":"2025","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.prp.2025.156025_bib6","first-page":"1","article-title":"Community prevalence of blood-borne viruses (hepatitis B and HIV) in Ireland","author":"McCormick","year":"2025","journal-title":"Ir. J. Med. Sci. (1971-)"},{"issue":"5","key":"10.1016\/j.prp.2025.156025_bib7","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021410","article-title":"Hepatitis B virus epidemiology","volume":"5","author":"MacLachlan","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.prp.2025.156025_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155991","article-title":"Epigenetic and post-translational modifications in ferroptosis regulation and hepatocellular carcinoma: new frontiers in therapeutic targeting","author":"Bolandi","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156025_bib9","article-title":"FAM72 family members serves as prognostic biomarker in liver hepatocellular carcinoma","volume":"269","author":"Naer","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156025_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1501139","article-title":"Association of hepatitis B virus DNA levels with efficacy and safety and the impact of antiviral therapy on prognosis in liver cancer patients receiving immune checkpoint inhibitors therapy: a systematic review and meta-analysis","volume":"16","author":"Cui","year":"2025","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2468-1253(20)30307-1","article-title":"Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis","volume":"6","author":"Tan","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.prp.2025.156025_bib12","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jmv.22135","article-title":"Aboriginal Taiwanese hepatitis B carriers have more favorable viral factors than Han Chinese carriers","volume":"83","author":"Nien","year":"2011","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.prp.2025.156025_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155928","article-title":"Harnessing immunotherapy for hepatocellular carcinoma: principles and emerging promises","author":"Miri","year":"2025","journal-title":"Pathol. -Res. Pract."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib14","article-title":"The prevalence of hepatitis B virus E antigen among Ghanaian blood donors","volume":"17","author":"Rufai","year":"2014","journal-title":"Pan Afr. Med. J."},{"issue":"3","key":"10.1016\/j.prp.2025.156025_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jceh.2017.11.009","article-title":"High prevalence of cirrhosis at initial presentation among safety-net adults with chronic hepatitis B virus infection","volume":"8","author":"Tang","year":"2018","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib16","first-page":"90","article-title":"Occult hepatitis B virus infection among Anti-HBc only positive individuals in the Southeast of Iran in high prevalence of HBV infection region","volume":"11","author":"Sharifi-Mood","year":"2009","journal-title":"Iran. Red Crescent Med. J. (IRCMJ)"},{"issue":"8","key":"10.1016\/j.prp.2025.156025_bib17","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/v13081463","article-title":"Mechanism of hepatitis B virus cccDNA formation","volume":"13","author":"Wei","year":"2021","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.prp.2025.156025_bib18","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/v14071504","article-title":"Occult hepatitis B virus infection: an update","volume":"14","author":"Saitta","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep4.1633","article-title":"Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus\/hepatitis delta virus coinfection","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol. Commun."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3350\/cmh.2021.0093","article-title":"Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus","volume":"28","author":"Kim","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"issue":"5","key":"10.1016\/j.prp.2025.156025_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.16538","article-title":"Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos (t) ide analogue treatment","volume":"54","author":"Xia","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.prp.2025.156025_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coviro.2018.01.007","article-title":"Role of HBx in hepatitis B virus persistence and its therapeutic implications","volume":"30","author":"Slagle","year":"2018","journal-title":"Curr. Opin. Virol."},{"issue":"9","key":"10.1016\/j.prp.2025.156025_bib23","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/v12090998","article-title":"Advanced therapeutics, vaccinations, and precision medicine in the treatment and management of chronic hepatitis b viral infections; where are we and where are we going?","volume":"12","author":"Duraisamy","year":"2020","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.prp.2025.156025_bib24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/jvh.12387","article-title":"Definition of an HB sAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms","volume":"22","author":"D\u00e9sir\u00e9","year":"2015","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.prp.2025.156025_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00401","article-title":"Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection","volume":"11","author":"Hoogeveen","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.prp.2025.156025_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.amjmed.2005.07.012","article-title":"Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination","volume":"118","author":"Sjogren","year":"2005","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/epirev\/mxj009","article-title":"Hepatitis B virus infection: epidemiology and vaccination","volume":"28","author":"Shepard","year":"2006","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.prp.2025.156025_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41698-022-00279-3","article-title":"Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer","volume":"6","author":"Guo","year":"2022","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"issue":"7916","key":"10.1016\/j.prp.2025.156025_bib31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41586-022-04857-0","article-title":"Structural insights into the HBV receptor and bile acid transporter NTCP","volume":"606","author":"Park","year":"2022","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.prp.2025.156025_bib32","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/vaccines11121862","article-title":"HBV vaccines: advances and development","volume":"11","author":"Mahmood","year":"2023","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/INF.0000000000001361","article-title":"Comparative efficacy, safety and immunogenicity of Hepavax-Gene TF and Engerix-B recombinant hepatitis B vaccines in neonates in China","volume":"36","author":"Zhu","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/v12020126","article-title":"Hepatitis B virus (HBV) subviral particles as protective vaccines and vaccine platforms","volume":"12","author":"Ho","year":"2020","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2567.2008.02896.x","article-title":"Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus","volume":"126","author":"Op den Brouw","year":"2009","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hep.30637","article-title":"Characteristics of impaired dendritic cell function in patients with hepatitis B virus infection","volume":"70","author":"Yonejima","year":"2019","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.prp.2025.156025_bib37","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/apt.16828","article-title":"Hepatitis B\u2014Current and emerging therapies","volume":"55","author":"Yardeni","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.prp.2025.156025_bib39","series-title":"Access to treatment for hepatitis B virus infection\u2014worldwide, 2016","first-page":"2595","author":"Hutin","year":"2018"},{"issue":"8","key":"10.1016\/j.prp.2025.156025_bib40","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.3390\/pharmaceutics15082070","article-title":"Dendritic cell-derived exosomes in cancer immunotherapy","volume":"15","author":"Luo","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.prp.2025.156025_bib41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nrmicro2332","article-title":"A look behind closed doors: interaction of persistent viruses with dendritic cells","volume":"8","author":"Lambotin","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"issue":"3","key":"10.1016\/j.prp.2025.156025_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/cmi.2014.95","article-title":"Dissecting the dendritic cell controversy in chronic hepatitis B virus infection","volume":"12","author":"Gehring","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"11","key":"10.1016\/j.prp.2025.156025_bib43","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/abbs\/gmv093","article-title":"Dendritic cell-based vaccination with lentiviral vectors encoding ubiquitinated hepatitis B core antigen enhances hepatitis B virus-specific immune responses in vivo","volume":"47","author":"Dai","year":"2015","journal-title":"Acta Biochim. Et. Biophys. Sin."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib44","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2007.02.055","article-title":"Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies","volume":"132","author":"Ni","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.prp.2025.156025_bib45","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/21645515.2016.1276125","article-title":"Research progress of therapeutic vaccines for treating chronic hepatitis B","volume":"13","author":"Li","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"6","key":"10.1016\/j.prp.2025.156025_bib46","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-based vaccines: current progress and future challenges","volume":"120","author":"Malonis","year":"2019","journal-title":"Chem. Rev."},{"issue":"01","key":"10.1016\/j.prp.2025.156025_bib47","article-title":"Therapeutic DNA Vaccines: The Final Step for Success","volume":"8","author":"Do Carmo","year":"2017","journal-title":"Bacteriol. Parasitol."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib48","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.patbio.2010.01.006","article-title":"Hepatitis B vaccines: protective efficacy and therapeutic potential","volume":"58","author":"Michel","year":"2010","journal-title":"Pathol. Biol."},{"issue":"3","key":"10.1016\/j.prp.2025.156025_bib49","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib50","article-title":"Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component","volume":"6","author":"Su","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.prp.2025.156025_bib51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"year":"2024","series-title":"Generation of multicistronic DNA-and mRNA-based therapeutic vaccines against chronic hepatitis B virus infection","author":"Kerth","key":"10.1016\/j.prp.2025.156025_bib52"},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1232","article-title":"Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures","volume":"10","author":"Jansen","year":"2021","journal-title":"Clin. Transl. Immunol."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1021\/acs.molpharmaceut.3c00907","article-title":"DNA-based nonviral gene therapy\u2500 challenging but promising","volume":"21","author":"Guan","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.prp.2025.156025_bib55","unstructured":"Beretta, M., et al., Enhanced hepatitis B virus-specific immunity by combined neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B infection. Hepatology: p. 10.1097."},{"issue":"3","key":"10.1016\/j.prp.2025.156025_bib56","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/liv.12530","article-title":"Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice","volume":"35","author":"Yoon","year":"2015","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib57","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.rchipe.2015.06.012","article-title":"Seroconversion in response to a reinforced primary hepatitis B vaccination in children with cancer","volume":"86","author":"Villena","year":"2015","journal-title":"Rev. Chil. De. Pediatr."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib58","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3748\/wjg.v23.i2.306","article-title":"Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy","volume":"23","author":"Yang","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.prp.2025.156025_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-020-00662-x","article-title":"HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice","volume":"27","author":"Horng","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib60","first-page":"143","article-title":"Immunomodulation therapy in children with chronic hepatitis B","volume":"98","author":"Karaoglan","year":"2006","journal-title":"J. Natl. Med. Assoc."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib61","article-title":"Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance","volume":"5","author":"Sacherl","year":"2023","journal-title":"JHEP Rep."},{"issue":"6","key":"10.1016\/j.prp.2025.156025_bib62","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2024.06.027","article-title":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","volume":"81","author":"Tak","year":"2024","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib63","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2022.12.013","article-title":"Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models","volume":"78","author":"Su","year":"2023","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.prp.2025.156025_bib64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/vaccines9080841","article-title":"Immunogenicity and antiviral response of therapeutic hepatitis B vaccination in a mouse model of HBeAg-negative, persistent HBV infection","volume":"9","author":"Kosinska","year":"2021","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.prp.2025.156025_bib65","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3390\/genes13111941","article-title":"Adenoviral vectors: potential as anti-HBV vaccines and therapeutics","volume":"13","author":"Farhad","year":"2022","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib66","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/infdis\/jiad340","article-title":"Alternating arenavirus vector immunization generates robust polyfunctional genotype cross-reactive hepatitis B virus\u2013specific CD8 T-cell responses and high anti\u2013hepatitis B surface antigen titers","volume":"229","author":"Schmidt","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.prp.2025.156025_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1155637","article-title":"A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine","volume":"14","author":"Choi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2025.156025_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1163118","article-title":"Induction of broad multifunctional CD8+\u2009and CD4+\u2009T cells by hepatitis B virus antigen-based synthetic long peptides ex vivo","volume":"14","author":"Jansen","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib69","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib70","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004836-200310000-00012","article-title":"The lack of effect of therapeutic vaccination with a pre-S2\/S HBV vaccine in the immune tolerant phase of chronic HBV infection","volume":"37","author":"Yalcin","year":"2003","journal-title":"J. Clin. Gastroenterol."},{"issue":"47","key":"10.1016\/j.prp.2025.156025_bib71","doi-asserted-by":"crossref","first-page":"17862","DOI":"10.1073\/pnas.0608578103","article-title":"An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection","volume":"103","author":"Huang","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.prp.2025.156025_bib72","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/vaccines12030237","article-title":"mRNA therapeutic vaccine for hepatitis B demonstrates immunogenicity and efficacy in the AAV-HBV mouse model","volume":"12","author":"De Pooter","year":"2024","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib73","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41541-024-00813-3","article-title":"A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression","volume":"9","author":"Zhao","year":"2024","journal-title":"npj Vaccin."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-025-01069-1","article-title":"HLA I immunopeptidome of synthetic long peptide pulsed human dendritic cells for therapeutic vaccine design","volume":"10","author":"Kessler","year":"2025","journal-title":"npj Vaccin."},{"issue":"7","key":"10.1016\/j.prp.2025.156025_bib75","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nri2103","article-title":"Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo","volume":"7","author":"Villadangos","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prp.2025.156025_bib77","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"elife"},{"issue":"3","key":"10.1016\/j.prp.2025.156025_bib78","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2567.2009.03179.x","article-title":"Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific","volume":"129","author":"Wu","year":"2010","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.prp.2025.156025_bib79","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2012.08.046","article-title":"Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection","volume":"143","author":"Martinet","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib80","first-page":"1","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"5","key":"10.1016\/j.prp.2025.156025_bib81","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.prp.2025.156025_bib82","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.immuni.2013.05.004","article-title":"Immune sensing of DNA","volume":"38","author":"Paludan","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib83","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s13238-012-2104-8","article-title":"Regulation of TLR7\/9 signaling in plasmacytoid dendritic cells","volume":"4","author":"Bao","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.prp.2025.156025_bib84","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fimmu.2019.00452","article-title":"Contribution of cytokines to tissue damage during human respiratory syncytial virus infection","volume":"10","author":"Bohmwald","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2025.156025_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2025.106977","article-title":"In virto priming of the STING signaling pathway enhances the maturation and activation of dendritic cells induced by hepatitis B vaccine","author":"Ren","year":"2025","journal-title":"Immunol. Lett."},{"issue":"14","key":"10.1016\/j.prp.2025.156025_bib86","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1128\/JVI.02903-15","article-title":"Hepatitis B virus surface antigen activates myeloid dendritic cells via a soluble CD14-dependent mechanism","volume":"90","author":"van Montfoort","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.prp.2025.156025_bib87","doi-asserted-by":"crossref","unstructured":"Sun HaiHua, S.H., Z.D. Zhou DongFang, and Z.J.Zhou JunYing, The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation. 2015.","DOI":"10.1002\/jmv.24306"},{"issue":"8","key":"10.1016\/j.prp.2025.156025_bib88","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nri3254","article-title":"Cross-presentation by dendritic cells","volume":"12","author":"Joffre","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.prp.2025.156025_bib89","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/embj.201488027","article-title":"Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming","volume":"33","author":"Dalod","year":"2014","journal-title":"EMBO J."},{"issue":"39","key":"10.1016\/j.prp.2025.156025_bib90","doi-asserted-by":"crossref","first-page":"14156","DOI":"10.3748\/wjg.v20.i39.14156","article-title":"Immunopathogenesis of chronic hepatitis B","volume":"20","author":"Balmasova","year":"2014","journal-title":"World J. Gastroenterol.: WJG"},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib91","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.intimp.2015.06.019","article-title":"Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection","volume":"27","author":"Wei","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib92","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12865-023-00571-2","article-title":"Function and autophagy of monocyte-derived dendritic cells is affected by hepatitis B virus infection","volume":"24","author":"Xu","year":"2023","journal-title":"BMC Immunol."},{"key":"10.1016\/j.prp.2025.156025_bib93","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00705-009-0521-7","article-title":"B7-DC-silenced dendritic cells induce stronger anti-HBV immunity in transgenic mice","volume":"154","author":"Fan","year":"2009","journal-title":"Arch. Virol."},{"issue":"10","key":"10.1016\/j.prp.2025.156025_bib94","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3748\/wjg.14.1617","article-title":"Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B","volume":"14","author":"Lu","year":"2008","journal-title":"World J. Gastroenterol.: WJG"},{"issue":"11","key":"10.1016\/j.prp.2025.156025_bib95","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.1021\/acsnano.7b04878","article-title":"The exosome total isolation chip","volume":"11","author":"Liu","year":"2017","journal-title":"ACS nano"},{"key":"10.1016\/j.prp.2025.156025_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155097","article-title":"Dendritic cell-derived exosomes (Dex): underlying the role of exosomes derived from diverse DC subtypes in cancer pathogenesis","volume":"254","author":"Tuluwengjiang","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.prp.2025.156025_bib97","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.celrep.2014.07.035","article-title":"Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells","volume":"8","author":"Squadrito","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.prp.2025.156025_bib98","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12935-024-03514-y","article-title":"Therapeutic combinations of exosomes alongside cancer stem cells (CSCs) and of CSC-derived exosomes (CSCEXs) in cancer therapy","volume":"24","author":"Touchaei","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2025.156025_bib99","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.intimp.2018.12.009","article-title":"In vitro analysis of immunomodulatory effects of mesenchymal stem cell-and tumor cell-derived exosomes on recall antigen-specific responses","volume":"67","author":"Fathollahi","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.prp.2025.156025_bib100","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2017.09.022","article-title":"Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma","volume":"411","author":"Liu","year":"2017","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2016.01.021","article-title":"Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses","volume":"374","author":"Dashti","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2025.156025_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155288","article-title":"Dendritic cell-derived exosome (DEX) therapy for digestive system cancers; recent advances and future prospect","author":"Al-Hawary","year":"2024","journal-title":"Pathol. -Res. Pract."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib103","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-022-03212-4","article-title":"Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors","volume":"13","author":"Ghasempour","year":"2022","journal-title":"Stem Cell Res. Ther."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/etm.2023.11866","article-title":"Exosomes from Ub\u2011HBcAg\u2011overexpressing dendritic cells induce T\u2011lymphocyte differentiation and enhance cytotoxic T\u2011lymphocyte activity","volume":"25","author":"Yang","year":"2023","journal-title":"Exp. Ther. Med."},{"issue":"6","key":"10.1016\/j.prp.2025.156025_bib105","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/hep.30548","article-title":"Exosomal interferon-induced transmembrane protein 2 transmitted to dendritic cells inhibits interferon alpha pathway activation and blocks anti\u2013hepatitis b virus efficacy of exogenous interferon alpha","volume":"69","author":"Shi","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib106","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tranon.2018.01.001","article-title":"Dendritic cells pulsed with exosomes in combination with PD-1 antibody increase the efficacy of sorafenib in hepatocellular carcinoma model","volume":"11","author":"Shi","year":"2018","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib107","doi-asserted-by":"crossref","DOI":"10.1002\/ctd2.173","article-title":"Dendritic cell-based immunotherapy: a potential therapeutic option for chronic Hepatitis B virus infection","volume":"3","author":"Wu","year":"2023","journal-title":"Clin. Transl. Discov."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib108","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/08820139.2012.744418","article-title":"Improvement of HBsAg gene-modified dendritic cell-based vaccine efficacy by optimizing immunization method or the application of \u03b2-glucosylceramide","volume":"42","author":"Long","year":"2013","journal-title":"Immunol. Investig."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib109","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2007.08.004","article-title":"Therapeutic potential of dendritic cell-based immunization against HBV in transgenic mice","volume":"77","author":"Jiang","year":"2008","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.prp.2025.156025_bib110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.humimm.2009.12.010","article-title":"Improvement of dendritic-based vaccine efficacy against hepatitis B virus\u2013related hepatocellular carcinoma by two tumor-associated antigen gene\u2013infected dendritic cells","volume":"71","author":"Yang","year":"2010","journal-title":"Hum. Immunol."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib111","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3892\/mmr.2015.4654","article-title":"Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus\u2011associated hepatocellular carcinoma","volume":"13","author":"Wang","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib112","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/21645515.2019.1689081","article-title":"A dendritic cell-targeted chimeric hepatitis B virus immunotherapeutic vaccine induces both cellular and humoral immune responses in vivo","volume":"16","author":"George","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib113","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.imlet.2015.10.007","article-title":"A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice","volume":"168","author":"Yu","year":"2015","journal-title":"Immunol. Lett."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib114","first-page":"295","article-title":"Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer","volume":"14","author":"Akbar","year":"2004","journal-title":"Int. J. Mol. Med."},{"issue":"6","key":"10.1016\/j.prp.2025.156025_bib115","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2893.2010.01320.x","article-title":"Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B","volume":"18","author":"Akbar","year":"2011","journal-title":"J. Viral Hepat."},{"issue":"7","key":"10.1016\/j.prp.2025.156025_bib116","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.imbio.2004.07.001","article-title":"Production of hepatitis B surface antigen-pulsed dendritic cells from immunosuppressed murine hepatitis B virus carrier: evaluation of immunogenicity of antigen-pulsed dendritic cells in vivo","volume":"209","author":"Furukawa","year":"2004","journal-title":"Immunobiology"},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28746","article-title":"Exosomes loading Tapasin enhance T cell immune response by autophagy to inhibit HBV replication","volume":"95","author":"Lv","year":"2023","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib118","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/vaccines9020147","article-title":"SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib119","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12951-024-02355-1","article-title":"An overview on mRNA-based vaccines to prevent monkeypox infection","volume":"22","author":"Natami","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.prp.2025.156025_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01339-1","article-title":"Clinical and immunological effects of mRNA vaccines in malignant diseases","volume":"20","author":"Heine","year":"2021","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib121","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.intimp.2015.06.019","article-title":"Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection","volume":"27","author":"Wei","year":"2015","journal-title":"Int Immunopharmacol."},{"issue":"6","key":"10.1016\/j.prp.2025.156025_bib122","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jhep.2007.07.019","article-title":"Response to interferon-alpha treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B","volume":"47","author":"Zhang","year":"2007","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib123","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.14045","article-title":"Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T-Cells Combined Antiviral Drugs in Treatment Naive CHB Patients-A Multi-Centre Phase II Study","volume":"32","author":"Gu","year":"2025","journal-title":"J. Viral Hepat."},{"issue":"12","key":"10.1016\/j.prp.2025.156025_bib124","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3748\/wjg.v11.i12.1806","article-title":"Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study","volume":"11","author":"Chen","year":"2005","journal-title":"World J. Gastroenterol.: WJG"},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1386-6346(01)00165-6","article-title":"Activation and maturation of antigen-presenting dendritic cells during vaccine therapy in patients with chronic hepatitis due to hepatitis B virus","volume":"23","author":"Horiike","year":"2002","journal-title":"Hepatol. Res."},{"issue":"13","key":"10.1016\/j.prp.2025.156025_bib126","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.vaccine.2010.01.038","article-title":"Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers","volume":"28","author":"Luo","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.prp.2025.156025_bib127","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.3892\/mmr.2017.7322","article-title":"Effect of the hepatitis B virus S\u2011ecdCD40L vaccine therapy in HBV transgenic mice: A vaccine\u2011induced activation of antigen presenting dendritic cells","volume":"16","author":"Guan","year":"2017","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.prp.2025.156025_bib128","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.6","article-title":"Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection","volume":"2","author":"Zabaleta","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jhep.2010.05.007","article-title":"A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals","volume":"53","author":"Gowans","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.prp.2025.156025_bib130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12026-017-8967-2","article-title":"Immunotherapy with interferon-\u03b1-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial)","volume":"66","author":"Chernykh","year":"2018","journal-title":"Immunol. Res."},{"issue":"10","key":"10.1016\/j.prp.2025.156025_bib131","doi-asserted-by":"crossref","first-page":"e40375","DOI":"10.5812\/hepatmon.40375","article-title":"Hepatitis C and G virus infection prevalence among hemodialysis patients and associated risk factors in the Hormozgan Province of Southern Iran","volume":"16","author":"Kargar Kheirabad","year":"2016","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.prp.2025.156025_bib132","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.prp.2025.156025_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001898","article-title":"Host genetic factors and vaccine-induced immunity to hepatitis B virus infection","volume":"3","author":"Hennig","year":"2008","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib134","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000625","article-title":"HBV and HBsAg strongly reshape the phenotype, function, and metabolism of DCs according to patients\u2019 clinical stage","volume":"9","author":"Dumolard","year":"2025","journal-title":"Hepatol. Commun."},{"issue":"9","key":"10.1016\/j.prp.2025.156025_bib135","first-page":"22","article-title":"Analysis of hepatitis B transmission risk factors in HIV patients","volume":"5","author":"Ghasemzadeh","year":"2016","journal-title":"Int. J. Med. Res. Health Sci."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib136","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.prp.2025.156025_bib137","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.prp.2025.156025_bib138","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2217\/fon-2017-0531","article-title":"Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions","volume":"14","author":"Handy","year":"2017","journal-title":"Future Oncol."},{"key":"10.1016\/j.prp.2025.156025_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2019.103968","article-title":"Nucleic acid vaccines for hepatitis B and C virus","volume":"75","author":"Karimkhanilouyi","year":"2019","journal-title":"Infect. Genet. Evol."},{"issue":"7","key":"10.1016\/j.prp.2025.156025_bib140","first-page":"61","article-title":"Implementation of hepatitis B birth dose vaccination--worldwide, 2016\/Mise en oeuvre de la vaccination contre l\u2032hepatite B par une dose a la naissance a l\u2032echelle mondiale, 2016","volume":"93","author":"Li","year":"2018","journal-title":"Wkly. Epidemiol. Rec."},{"issue":"5","key":"10.1016\/j.prp.2025.156025_bib141","doi-asserted-by":"crossref","first-page":"e1141","DOI":"10.1542\/peds.2014-3213","article-title":"Outcomes of infants born to women infected with hepatitis B","volume":"135","author":"Schillie","year":"2015","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.prp.2025.156025_bib142","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2010.12.031","article-title":"Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges","volume":"54","author":"Michel","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.prp.2025.156025_bib143","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.virusres.2018.02.016","article-title":"Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies","volume":"248","author":"Bartenschlager","year":"2018","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib144","doi-asserted-by":"crossref","first-page":"9251","DOI":"10.1038\/s41598-019-45461-z","article-title":"Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery","volume":"9","author":"Christiansen","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/stem.3095","article-title":"Induced pluripotent stem cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy","volume":"38","author":"Horton","year":"2020","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib146","doi-asserted-by":"crossref","first-page":"39","DOI":"10.26502\/ami.93650075","article-title":"Activation of human dendritic cells by nanoparticles carrying CTL epitopes of non-structural proteins of hepatitis C virus","volume":"6","author":"Victor","year":"2022","journal-title":"Arch. Microbiol. Immunol."},{"key":"10.1016\/j.prp.2025.156025_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.719664","article-title":"New approaches to dendritic cell-based therapeutic vaccines against HIV-1 infection","volume":"12","author":"Espinar-Buitrago","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.prp.2025.156025_bib148","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib149","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jhep.2022.03.011","article-title":"Blocking CD47 promotes antitumour immunity through CD103+\u2009dendritic cell\u2013NK cell axis in murine hepatocellular carcinoma model","volume":"77","author":"Wang","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.prp.2025.156025_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.livres.2023.11.004","article-title":"Hepatocellular carcinoma recurrence: Predictors and management\u2606","author":"Abdelhamed","year":"2023","journal-title":"Liver Res."},{"key":"10.1016\/j.prp.2025.156025_bib151","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.601710","article-title":"Etiology of hepatocellular carcinoma: special focus on fatty liver disease","volume":"10","author":"Suresh","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2025.156025_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1261575","article-title":"Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.prp.2025.156025_bib153","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jcyt.2023.11.014","article-title":"Phospholipid scramblase 1 is involved in immunogenic cell death and contributes to dendritic cell\u2013based vaccine efficiency to elicit antitumor immune response in vitro","volume":"26","author":"Montico","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.prp.2025.156025_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105655","article-title":"Plant-based vaccines and cancer therapy: Where are we now and where are we going?","volume":"169","author":"Rahimian","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prp.2025.156025_bib155","first-page":"3003","article-title":"Osteopontin promotes dendritic cell maturation and function in response to HBV antigens","author":"Cui","year":"2015","journal-title":"Drug Des., Dev. Ther."},{"key":"10.1016\/j.prp.2025.156025_bib156","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.prp.2025.156025_bib157","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.medj.2021.03.002","article-title":"The therapeutic landscape of hepatocellular carcinoma","volume":"2","author":"Gallage","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.prp.2025.156025_bib158","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.721975","article-title":"HBV-specific CD8+\u2009T-cell tolerance in the liver","volume":"12","author":"Baudi","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2025.156025_bib159","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2249.2010.04226.x","article-title":"Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8+\u2009T cell\/regulatory T cells in tumour","volume":"162","author":"Song","year":"2010","journal-title":"Clin. Exp. Immunol."},{"issue":"7086","key":"10.1016\/j.prp.2025.156025_bib160","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature04651","article-title":"Chemokines enhance immunity by guiding naive CD8+\u2009T cells to sites of CD4+\u2009T cell\u2013dendritic cell interaction","volume":"440","author":"Castellino","year":"2006","journal-title":"Nature"},{"issue":"118","key":"10.1016\/j.prp.2025.156025_bib161","first-page":"489","article-title":"The immunosuppression role of alpha-fetoprotein in human hepatocellular carcinoma","volume":"21","author":"Meng","year":"2016","journal-title":"Discov. Med."},{"issue":"7","key":"10.1016\/j.prp.2025.156025_bib162","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2174\/156652411800615162","article-title":"Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine","volume":"11","author":"Bei","year":"2011","journal-title":"Curr. Mol. Med."},{"issue":"3","key":"10.1016\/j.prp.2025.156025_bib163","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2089","article-title":"Therapeutic efficacy of hepatitis B virus vaccine in treatment of chronic HBV infections: A systematic review and meta-analysis","volume":"30","author":"Ghozy","year":"2020","journal-title":"Rev. Med. Virol."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib164","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/mmt-2016-0014","article-title":"Dendritic cell vaccines for melanoma: past, present and future","volume":"3","author":"Dillman","year":"2016","journal-title":"Melanoma Manag"},{"issue":"19","key":"10.1016\/j.prp.2025.156025_bib165","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1042\/CS20210577","article-title":"How dendritic cells sense and respond to viral infections","volume":"135","author":"Marongiu","year":"2021","journal-title":"Clin. Sci."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib166","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1473-3099(21)00076-1","article-title":"Bell's palsy and SARS-CoV-2 vaccines","volume":"21","author":"Ozonoff","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.prp.2025.156025_bib167","series-title":"Seminars in oncology","article-title":"Vaccines, adjuvants, and dendritic cell activators\u2014current status and future challenges","author":"Obeid","year":"2015"},{"issue":"6","key":"10.1016\/j.prp.2025.156025_bib168","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1586\/1744666X.2014.907742","article-title":"Future considerations for dendritic cell immunotherapy against chronic viral infections","volume":"10","author":"Atanley","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.prp.2025.156025_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155983","article-title":"Vaccination and personalized cancer vaccines focusing on common cancers in women: a narrative review","author":"Ghahfarrokhi","year":"2025","journal-title":"Pathol. -Res. Pract."},{"issue":"10","key":"10.1016\/j.prp.2025.156025_bib170","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","article-title":"Dendritic cell-based vaccines: barriers and opportunities","volume":"8","author":"Cintolo","year":"2012","journal-title":"Future Oncol."},{"issue":"4","key":"10.1016\/j.prp.2025.156025_bib171","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2567.2012.03590.x","article-title":"Dendritic cell-based immunity and vaccination against hepatitis C virus infection","volume":"136","author":"Zhou","year":"2012","journal-title":"Immunology"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825002171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825002171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T02:30:48Z","timestamp":1749004248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825002171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":171,"alternative-id":["S0344033825002171"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156025","relation":{},"ISSN":["0344-0338"],"issn-type":[{"type":"print","value":"0344-0338"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the progress and challenges of developing dendritic-based vaccines against hepatitis B virus (HBV)","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156025"}}